NIAID Banner Logo Image

HIV Drugs in Development


Drug ClassSponsor and/or CompanyDrug NameAlt NameDrug StatusNotesAIDS#
Antibody, Broadly NeutralizingNational Institute of Allergy and Infectious Diseases (NIAID) SAR441236A tri-specific broadly neutralizing antibody against HIVPhase 1Active, Not Recruiting 
Antibody, MonoclonalNational Institutes of Health Clinical Center (CC)Pembrolizumab Phase 1Recruiting 
Antibody, MonoclonalSt George's, University of LondonP2G12 Phase 1Not Yet Recruiting 578224
Antibody, MonoclonalMacroGenics; National Institute of Allergy and Infectious Diseases (NIAID)MGD014JNJ-64052781; HIV-1 x CD3 bispecific DART moleculePhase 1Recruiting 
Antibody, MonoclonalOttawa Hospital Research Institute Entyvio™Vedolizumab; A humanized monoclonal antibodyPhase 2Recruiting 
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)CemiplimabAnti-PD-1 AntibodyPhase 1/2Active, Not Recruiting 
Antibody, MonoclonalRockefeller University3BNC117 -LS Phase 1Active, Not Recruiting 
Antibody, MonoclonalRockefeller University10-1074 Phase 1Completed 
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)VRC07-523LSVRC07-523-LS; VRC-HIVMAB075-00-ABPhase 1/2Recruiting 599294
Antibody, MonoclonalUnited BioPharmaUB-421Monoclonal antibody; mAb dB4C7Phase 3Not Yet Recruiting 
CRM1 InhibitorKaryopharm TherapeuticsVerdinexorKPT335Phase 1Completed 
Capsid InhibitorGilead SciencesLenacapavirGS-6207Phase 1Active, Not Recruiting 599611
CombinationRockefeller University10-1074-LS-J and 3BNC117-LS-JTwo broadly neutralizing monoclonal antibodiesPhase 1/2Recruiting 
Combination Janssen Pharmaceuticals, Inc.; ViiV HealthcareCabenuva™Rilpivirine and CabotegravirNew Drug Application (NDA) Submitted (April 2019)  
CombinationSt. Stephen's AIDS TrustTivicay™ and Rezolsta™Dolutegravir & Darunavir & CobicistatPhase 1Completed 
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-T Phase 1/2Recruiting 
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-HSCSB-728mR-HSPCPhase 1Active, Not Recruiting 
Entry and/or Fusion InhibitorPfizerPF-00232798 Phase 2Completed 582838
Entry and/or Fusion InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); GenzymeMavorixaforAMD-070; AMD-11070; X4P-001Phase 1/2Completed 495149
Entry and/or Fusion InhibitorCytoDyn, Inc.LeronlimabPRO-140; PA14Phase 2/3Recruiting 088103
Entry and/or Fusion InhibitorIncyte CorporationINCB-009471INCB-9471Phase 2Completed 503495
Entry and/or Fusion InhibitorViiV HealthcareFostemsavirGSK3684934; BMS-663068; prodrug of BMS-626529New Drug Application (NDA) Submitted (Dec 2019)  607788
Entry and/or Fusion InhibitorTobira TherapeuticsCenicrivirocTBR-652; TAK-652Phase 2Completed 224423
Entry and/or Fusion InhibitorRapid PharmaceuticalsAdaptavirRAP101; monomeric d-Ala-peptide T-amide (mDAPTA)Phase 2Unknown 052004
Entry and/or Fusion InhibitorViiV HealthcareCombinectinGSK3732394; BMS-986197Phase 1Recruiting 594670
Entry and/or Fusion InhibitorViiV Healthcare; GlaxoSmithKlineTemsavirBMS-626529Phase 1Completed 345401
Fusion InhibitorFrontier Biotechnologies Co., LtdAlbuvirtideABT; FB006M; Aikening™Phase 3Unknown 531982
HIV Latency Reversing AgentImmune System Regulation ABTriptorelinGonadotropin Releasing Hormone AgonistPhase 2Recruiting 
HIV Latency Reversing AgentThe Peter Doherty Institute for Infection and ImmunityAntabuse™ and Zolinza™Disulfiram and VorinostatPhase 1/2Terminated 
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorShenzhen Chipscreen Biosciences Co., LtdEpidaza™CS-055; Chidamide; HBI-8000Phase 2/3Unknown 
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorMcGill University Health Center; Abbott LabsDepakote™Valproic acid, Divalproex sodium; Valproate(VPA)Phase 2Unknown 057177
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorMassachusetts General Hospital; NovartisFarydak™PanobinostatPhase 1/2Recruiting 580714
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorAarhus University HospitalIstodax™RomidepsinPhase 2Recruiting 565088
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorImperial College London; MerckZolinza™Vorinostat; MK-0683; Suberoylanilide Hydroxamic Acid (SAHA); CCRIS 8456Phase 2Active, Not Recruiting 186714
HIV Latency-Reversing Agent; Toll-Like Receptor 3 (TLR-3) AgonistNational Institute of Allergy and Infectious Diseases (NIAID); Oncovir, Inc.Hiltonol™Poly-ICLCPhase 1/2Completed 187148
ImmunomodulatorThe Research Council of NorwayArcoxia™EtoricoxibPhase 2Completed 
ImmunomodulatorNational Institute of Allergy and Infectious Diseases (NIAID)Arava™LeflunomidePhase 1Completed 009747
ImmunomodulatorNational Institute of Allergy and Infectious Diseases (NIAID); Pfizer (Wyeth)Ammonium Trichlorotellurate; OssireneAS-101Phase 1Completed 000042
ImmunomodulatorFred Hutchinson Cancer Research CenterCellCept™; Myfortic™Mycophenolate Mofetil; MMFPhase 2Active, Not Recruiting 059828
ImmunomodulatorMerckPEG-Intron™; Pegasys™PEG IFN alpha-2aPhase 3Completed 
ImmunomodulatorUniversity of AarhusLefitolimodMGN-1703Phase 2Recruiting 
ImmunomodulatorUniversity of MinnesotaIL-15Interleukin 15Phase 1Completed 398478
ImmunomodulatorGeorgetown University; AmgenEnbrel™Etanercept; p75 TNFR-Fc fusion proteinPhase 1Completed 
Integrase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare; GlaxoSmithKlineCabotegravirGSK1265744; S-265744Phase 2/3Recruiting 598037
Integrase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare; GlaxoSmithKlineCabotegravir, Long-acting InjectableGSK1265744; S-265744Phase 3Recruiting 598037
Integrase InhibitorBoehringer IngelheimBI-224436 Phase 1Completed 566575
Integrase InhibitorViiV Healthcare; GlaxoSmithKlineGSK1247303 Phase 1Terminated 
Integrase InhibitorGilead SciencesBictegravirBIC; GS-9883Phase 2Terminated 592431
Janus Kinase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID)Ruxolitinib Phase 2Completed 564288
Maturation Inhibitor GlaxoSmithKlineGSK2838232 Phase 2Completed 
Maturation InhibitorViiV HealthcareGSK3640254 Phase 2Completed 
MicrobicidePopulation CouncilGriffithsin Gel Phase 1Completed 336134
MicrobicideGlaxoSmithKlineGSK706769 Phase 1Completed 
MicrobicideNational Institute of Allergy and Infectious Diseases (NIAID); Population CouncilPC-1005MIV-150 and Zinc Acetate and Carrageenan GelPhase 1Completed 
MicrobicideCentre for the AIDS Programme of Research in South Africa; Gilead SciencesTenofovir gelGS-1278; PMPA gel; Apropovir; TFVPhase 2/3Completed 021800
MicrobicideCONRAD; Uniroyal; Crompton Corp; BiosynUC781ThiocarboxanilidePhase 1Completed 029940
MicrobicideStarpharma Pty LtdVivaGel™SPL-7013 gelPhase 1/2Completed 223863
MicrobicideMyrexis, Inc.; Panacos PharmaceuticalsBevirimatBVM; PA-457; MPC-4326; DSB; YK-FH312Phase 2Completed 028530
MicrobicideReprotect, Inc.BufferGel™Carbomer 974P; Carbopol 974P; Carbopol polymerPhase 2/3Completed 180064
MicrobicideInternational Partnership for Microbicides, Inc.; Tibotec Pharmaceuticals; Janssen; Johnson & JohnsonDapivirineTMC-120; GEL-02; R147681; DAPPhase 3Completed 105293
MicrobicideInternational Partnership for Microbicides, Inc.DS003BMS793Phase 1Completed 335384
MicrobicideJohns Hopkins UniversityDuoGelIQP-0528Phase 1Completed 104929
NNRTIViriomElpivirineVM-1500, prodrug of elsulfavirinePhase 2/3Completed 
NNRTIViriomElpida™Elsulfavirine; VM-1500A (long acting injection)Phase 1Not Yet Recruiting 
NNRTIBoehringer IngelheimBILR 355 BSBILR-355Phase 2Terminated 212773
NNRTISt. Stephen's AIDS TrustTMC278-LAA long-acting formulation of Janssen's RilpivirinePhase 2Completed 169030
NNRTIKainos Medicine Inc.KM-023 Phase 1Completed 
NRTIKoronisKP-1461 (Prodrug of KP1212)SN-1461 (Prodrug of SN1212)Phase 2Terminated 293211
NRTIMerckMK-8504Prodrug of tenofovirPhase 1Completed 
NRTIMerckMK-8583Prodrug of tenofovirPhase 1Completed 
NRTIMerckIslatravirEFdA; MK-8591Phase 2Recruiting 343654
NRTIGilead SciencesGS-9131Prodrug of GS-9148Phase 2Terminated 354427
NRTIAchillion Pharmaceuticals; Vion PharmaceuticalsElvucitabineACH-126443; beta-L-Fd4CPhase 2Completed 060327
NRTIOncolys BioPharma; Brisol-Myers SquibbCensavudine; (renaming of Festinavir)4'-ethynyl-d4T; BMS-986001; OBP-601Phase 2Terminated 209894
NRTIRFS Pharma; Biochem Pharma; Triangle Pharmaceuticals; Gilead SciencesAmdoxovirDAPDPhase 2Withdrawn 005431
NRTIGlaxoSmithKline; Pharmasset, Inc.RacivirRCV; (+/-)FTC; 5-FSddC; LDS-022; PSI 5004Phase 2Completed 005245
NRTIGilead SciencesVemlidy™Tenofovir Alafenamide (Prodrug of tenofovir); GS-7340Phase 3Completed 046774
NRTI Incyte Corporation; Pharmasset; Dupont Pharmaceuticals; VionReverset™Dexelvucitabine; DFC; 5F-D4C; beta D-d4FC; DPC 817; RA 131423; RVTPhase 2Terminated 000572
Protease InhibitorConcert PharmaceuticalsC-10276Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10297Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10299Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorTaiMed Biologics Inc.TMB-607PPL-100; MK-8122Phase 1Terminated 
Protease InhibitorTibotec PharmaceuticalsTMC-310911 Phase 2Completed 483146
Proteasome InhibitorMayo ClinicNinlaro™IxazomibPhase 1Active, Not Recruiting 589853
Rev InhibitorAbivax SAABX464 Phase 2Completed 516635
Toll-Like Receptor 7 (TLR-7) AgonistGilead SciencesVesatolimodGS-9620Phase 2Recruiting 574840
UnidentifiedMerckMK-1972 Phase 1Terminated 
UnidentifiedMerck MK-8527 Phase 1Completed 
UnidentifiedMerckMK-4250 Phase 1Completed 
UnidentifiedMerck MK-8558 Phase 1Completed 

Sources: ClinicalTrials.gov and sponsor websites.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: May 2020